Adaptimmune Therapeutics announced that two key executive leadership team members based in the UK will be stepping down from their roles in 2025. Helen Tayton-Martin, Ph.D., M.B.A., Adaptimmune Co-Founder and Chief Business & Strategy Officer, will depart on March 31, 2025. Gavin Wood, Chief Financial Officer, will step down on May 31, 2025.
These changes are part of the company's previously announced strategic restructuring, which includes an approximately 33% reduction in headcount and targets around $300 million in aggregate cost savings over the next four years. The restructuring aims to focus an increasing proportion of Adaptimmune's corporate functions in the U.S.
Adrian Rawcliffe, Adaptimmune's Chief Executive Officer, acknowledged Dr. Tayton-Martin's integral role since co-founding the company in 2008 and Mr. Wood's substantial contributions since joining in 2020, including leading financial strategy through successful financings and the approval of TECELRA. Further plans for the re-organized team will be communicated in due course.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.